MCID: SPC010
MIFTS: 40

Speech and Communication Disorders

Categories: Mental diseases

Aliases & Classifications for Speech and Communication Disorders

MalaCards integrated aliases for Speech and Communication Disorders:

Name: Speech and Communication Disorders 38 40
Communication Disorder 38 12 14
Language Disorders 51 41 69
Language Disorder 38 12 14
Communication Disorders 51 41
Speech and Language Disorder 69
Speech Language Disorder 38
Communication Impairment 69

Classifications:



External Ids:

Disease Ontology 12 DOID:2033 DOID:93
ICD10 32 F80.9
NCIt 46 C2958 C97155

Summaries for Speech and Communication Disorders

MedlinePlus : 40 Many disorders can affect our ability to speak and communicate. They range from saying sounds incorrectly to being completely unable to speak or understand speech. Causes include Hearing disorders and deafness Voice problems, such as dysphonia or those caused by cleft lip or palate Speech problems like stuttering Developmental disabilities Learning disorders Autism spectrum disorder Brain injury Stroke Some speech and communication problems may be genetic. Often, no one knows the causes. By first grade, about 5 percent of children have noticeable speech disorders. Speech and language therapy can help. NIH: National Institute on Deafness and Other Communication Disorders

MalaCards based summary : Speech and Communication Disorders, also known as communication disorder, is related to expressive language disorder and stuttering, and has symptoms including other symbolic dysfunction, aprosodia and neurobehavioral manifestations. An important gene associated with Speech and Communication Disorders is FOXP2 (Forkhead Box P2), and among its related pathways/superpathways are Neuroscience and Alzheimers Disease Pathway. The drugs Dopamine and Levodopa have been mentioned in the context of this disorder. Affiliated tissues include brain, and related phenotypes are cellular and behavior/neurological

Disease Ontology : 12 A specific developmental disorder that involves specific developmental disorders of speech and language.

Wikipedia : 72 A communication disorder is any disorder that affects an individual\'s ability to comprehend, detect, or... more...

Related Diseases for Speech and Communication Disorders

Diseases related to Speech and Communication Disorders via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 77)
# Related Disease Score Top Affiliating Genes
1 expressive language disorder 31.8 FOXP2 PSEN1 TARDBP
2 stuttering 31.6 CNTNAP2 FOXP2 GNPTG
3 speech disorder 31.5 CNTNAP2 FOXP2 GNPTG GRN KIAA0319
4 cluttering 10.8
5 mixed receptive-expressive language disorder 10.8
6 childhood apraxia of speech 10.6 CNTNAP2 FOXP2
7 meniere disease 10.6
8 usher syndrome 10.6
9 acoustic neuroma 10.6
10 agnosia 10.6
11 swallowing disorders 10.6
12 frontotemporal lobar degeneration with tdp43 inclusions, grn-related 10.6 GRN MAPT
13 alzheimer disease 4 10.6 APOE PSEN1
14 posterior cortical atrophy 10.6 APOE MAPT
15 amusia 10.6 GRN PLG
16 writing disorder 10.6 GRN PSEN1
17 prosopagnosia 10.6 GRN PSEN1
18 phonagnosia 10.6 GRN PSEN1 TARDBP
19 associative agnosia 10.6 GRN PSEN1 TARDBP
20 familial idiopathic basal ganglia calcification 10.6 APOE MAPT PSEN1
21 alzheimer disease 2 10.6 APOE MAPT PSEN1
22 cerebral amyloid angiopathy, cst3-related 10.6 APOE MAPT PSEN1
23 vascular dementia 10.5 APOE MAPT PSEN1
24 perry syndrome 10.5 C9orf72 GRN TARDBP
25 intracranial vasospasm 10.5 APOE KANTR
26 autoimmune encephalitis 10.5 CNTNAP2 TRPV1
27 mutism 10.5 CNTNAP2 GRN
28 amyotrophic lateral sclerosis 18 10.5 C9orf72 TARDBP
29 articulation disorder 10.5 CNTNAP2 FOXP2 GNPTG
30 acute anterolateral myocardial infarction 10.5 KANTR PLG
31 semantic dementia 10.5 APOE GRN MAPT TARDBP
32 posterolateral myocardial infarction 10.5 KANTR PLG
33 cicatricial ectropion 10.5 CBS KANTR
34 facial neuralgia 10.5 KANTR PLG
35 kluver-bucy syndrome 10.5 MAPT PSEN1
36 cerebral falx meningioma 10.5 KANTR PLG
37 visual agnosia 10.5 GRN KANTR PSEN1
38 progressive non-fluent aphasia 10.5 C9orf72 GRN MAPT PSEN1
39 echolalia 10.5 CBS GRN MAPT PSEN1
40 behavioral variant of frontotemporal dementia 10.5 C9orf72 GRN MAPT PSEN1
41 inclusion body myositis 10.4 APOE MAPT TARDBP
42 apraxia 10.4 C9orf72 FOXP2 GRN MAPT
43 postencephalitic parkinson disease 10.4 KANTR MAPT TARDBP
44 pervasive developmental disorder 10.4 CNTNAP2 FOXP2 MECP2
45 apical myocardial infarction 10.4 KANTR PLG
46 motor neuron disease 10.4 C9orf72 GRN MAPT TARDBP
47 cerebral arteritis 10.4 KANTR PLG
48 leech infestation 10.4 KANTR PLG
49 reading disorder 10.4 CNTNAP2 FOXP2 KIAA0319 PSEN1
50 alexia 10.4 APOE KANTR PSEN1 TARDBP

Graphical network of the top 20 diseases related to Speech and Communication Disorders:



Diseases related to Speech and Communication Disorders

Symptoms & Phenotypes for Speech and Communication Disorders

UMLS symptoms related to Speech and Communication Disorders:


other symbolic dysfunction, aprosodia, neurobehavioral manifestations, lethargy

MGI Mouse Phenotypes related to Speech and Communication Disorders:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.15 L1CAM TARDBP APOE MAPT C9orf72 MECP2
2 behavior/neurological MP:0005386 10.1 L1CAM APOE MAPT C9orf72 MECP2 CNTNAP2
3 growth/size/body region MP:0005378 10.06 TARDBP L1CAM APOE MAPT C9orf72 MECP2
4 nervous system MP:0003631 9.93 L1CAM TARDBP APOE MAPT C9orf72 MECP2
5 integument MP:0010771 9.86 L1CAM APOE MAPT MECP2 CNTNAP2 PLG
6 no phenotypic analysis MP:0003012 9.56 L1CAM TARDBP APOE MAPT C9orf72 MECP2
7 taste/olfaction MP:0005394 8.92 APOE MAPT CNTNAP2 TRPV1

Drugs & Therapeutics for Speech and Communication Disorders

Drugs for Speech and Communication Disorders (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 309)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 51-61-6, 62-31-7 681
2
Levodopa Approved Phase 4,Phase 2,Phase 3,Not Applicable 59-92-7 6047
3
Topiramate Approved Phase 4 97240-79-4 5284627
4
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 19982-08-2 4054
5
Haloperidol Approved Phase 4 52-86-8 3559
6
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
7
Donepezil Approved Phase 4 120014-06-4 3152
8
Amphetamine Approved, Illicit, Investigational Phase 4 300-62-9 3007 5826
9
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
10
Methylphenidate Approved, Investigational Phase 4 20748-11-2, 113-45-1 4158
11
Citalopram Approved Phase 4 59729-33-8 2771
12
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
13
Corticosterone Experimental Phase 4,Phase 1,Early Phase 1 50-22-6 5753
14 Antiparkinson Agents Phase 4,Phase 2,Phase 3,Not Applicable
15 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Dopamine Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
17 Dopamine agonists Phase 4,Not Applicable
18 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
19 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Anticonvulsants Phase 4,Phase 2,Phase 3,Phase 1
22 Anti-Obesity Agents Phase 4
23 Neuroprotective Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
25 Excitatory Amino Acids Phase 4,Phase 3,Phase 2,Not Applicable
26 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Not Applicable
27 Nootropic Agents Phase 4,Phase 2,Phase 1,Not Applicable
28 adderall Phase 4,Phase 2
29 Central Nervous System Stimulants Phase 4,Phase 2,Not Applicable
30 Dopamine Uptake Inhibitors Phase 4,Phase 2
31 Analgesics Phase 4,Phase 2,Phase 3,Not Applicable
32 Antiemetics Phase 4,Phase 3
33 Antipsychotic Agents Phase 4,Phase 3,Phase 2
34 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 decanoic acid Phase 4
36 Dopamine Antagonists Phase 4,Phase 3,Phase 2
37 Gastrointestinal Agents Phase 4,Phase 3,Phase 1
38 Haloperidol decanoate Phase 4
39 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40
Serotonin Phase 4,Phase 3 50-67-9 5202
41 Serotonin Agents Phase 4,Phase 3
42 Serotonin Uptake Inhibitors Phase 4
43 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Cholinergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
45 Cholinesterase Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
46 Adrenergic Agents Phase 4,Not Applicable
47 Adrenergic Agonists Phase 4,Not Applicable
48 Adrenergic alpha-2 Receptor Agonists Phase 4
49 Adrenergic alpha-Agonists Phase 4,Not Applicable
50 Antihypertensive Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 640)

# Name Status NCT ID Phase Drugs
1 Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dyslexia Unknown status NCT00111371 Phase 4 Levodopa
2 Topiramate Treatment for Patients With Epilepsy and Learning Disability : A Prospective Observational Study Unknown status NCT00956696 Phase 4 topiramate
3 Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:A Randomized Controlled Trial Unknown status NCT00196703 Phase 4 memantine
4 Omega 3/6 Fatty Acids for Reading in Children Completed NCT02557477 Phase 4
5 Neuromuscular Electroestimulation and Respiratory Muscle Training in Subacute Stroke Completed NCT02473432 Phase 4
6 Efficacy Study of Switching Stabilized Schizophrenic Patients From Conventional to Atypical Antipsychotic Treatment Completed NCT00191555 Phase 4 olanzapine;haloperidol
7 Memantine and Intensive Speech-Language Therapy in Aphasia Completed NCT00640198 Phase 4 memantine;memantine;placebo
8 Donepezil in Chronic Poststroke Aphasia: a Randomized Controlled Trial Completed NCT00196690 Phase 4 Donepezil
9 Dopaminergic Enhancement of Learning and Memory in Aphasia Completed NCT00102869 Phase 4 levodopa
10 Interventions for Children With Attention and Reading Disorders Completed NCT01133847 Phase 4 Methylphenidate;Mixed Salt Amphetamine;Atomoxetine;Guanfacine
11 Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia Completed NCT00607919 Phase 4 Atomoxetine;Placebo
12 Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia Completed NCT00716274 Phase 4 Atomoxetine;Placebo
13 Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia Completed NCT00545974 Phase 4 memantine;Placebo pill
14 Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia Completed NCT00376051 Phase 4 Citalopram
15 Comparison of Atomoxetine and Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Reading Disorder (RD) Completed NCT00191906 Phase 4 Atomoxetine Hydrochloride;placebo
16 Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD Completed NCT00191048 Phase 4 Atomoxetine
17 Imaging of Brain Amyloid Plaques in the Aging Population Enrolling by invitation NCT00950430 Phase 4 Pittsburgh Compound B (C-11 PiB);F-18 FDG;Tau (18-F-AV-1451)
18 Drug to Prevent Pneumonia in the Tube Fed Terminated NCT02358642 Phase 4 Angiotensin converting enzyme inhibitor (Lisinopril);Placebo
19 Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD) Withdrawn NCT00127114 Phase 4 Amantadine;Placebo
20 Randomized Clinical Trial of Phonological Interventions Unknown status NCT00818428 Phase 2, Phase 3
21 Feasibility of Omega-3 Supplementation for Children With Language Impairments Unknown status NCT01640106 Phase 3
22 Effectiveness of Early Parent-Based Language Intervention Unknown status NCT00625261 Phase 3
23 Effects of MTS-r on Speech Production in Non-fluent Aphasia Post-ischemic Stroke Patients Unknown status NCT02241213 Phase 3
24 Enhancing Self-Understanding and Social Integration of Middle School Students With Learning Disabilities Unknown status NCT00246792 Phase 2, Phase 3
25 Improvement of Language Disturbances After Stroke by Intensive Training and Electrical Brain Stimulation Unknown status NCT00822068 Phase 2, Phase 3
26 Effects of OroPharyngeal Exercises on Patients With Moderate Obstructive Sleep Apnea Completed NCT00660777 Phase 3
27 A Comparison of Language Intervention Programs Completed NCT00033150 Phase 3
28 Use of Acupuncture In Children With Autistic Spectrum Disorder Completed NCT00346736 Phase 3
29 Balance Training in Parkinson's Disease Using Cues Completed NCT01960985 Phase 3
30 Acute Otitis Media: Adjuvant Therapy to Improve Outcome Completed NCT00000363 Phase 3 Antihistamine;Corticosteroid
31 Xylitol Syrup for the Prevention of Acute Otitis Media in Otitis-prone Children Completed NCT01044030 Phase 3 Xylitol syrup;Placebo
32 Sudden Deafness Treatment Trial Completed NCT00097448 Phase 3 prednisone;methylprednisolone sodium succinate
33 Secretin for the Treatment of Autism Completed NCT00065962 Phase 3 secretin, synthetic porcine;secretin, biologically derived porcine
34 Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease Completed NCT01028053 Phase 3 Flutemetamol (18F) Injection
35 Augmenting Language Therapy for Aphasia: Levodopa Completed NCT01429077 Phase 2, Phase 3 levodopa/carbidopa;Placebo comparator
36 A Prospective Study of Risperdal (Risperidone) for the Treatment of Behavioral Disorder Following Psychological Therapy for Challenging Behavior in Learning Disabled Children Completed NCT00254930 Phase 3 risperidone
37 A Study to Assess the Efficacy and Safety of Pagoclone for Adults With Stuttering Completed NCT00830154 Phase 2, Phase 3 pagoclone
38 Reading Problems in Children Living in Urban Areas Completed NCT00065832 Phase 3
39 Application of Miglustat in Patients With Niemann-Pick Type C Completed NCT01760564 Phase 3 Miglustat
40 Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) Completed NCT01626378 Phase 3 TRx0237;Placebo
41 Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia Completed NCT00594737 Phase 3 memantine hydrochloride
42 Stem Cell Transplant for Inborn Errors of Metabolism Completed NCT00176904 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Antithymocyte Globulin
43 Tinnitus Retraining Therapy Trial Completed NCT01177137 Phase 3
44 Efficacy and Tolerability of Ecopipam in Adults With Childhood Onset Fluency Disorder (Stuttering). Recruiting NCT02909088 Phase 2, Phase 3 Ecopipam 50mg;Ecopipam 100mg
45 Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy Recruiting NCT02839642 Phase 3 Rivastigmine;Placebo
46 Melodic-Intonation-Therapy and Speech-Repetition-Therapy for Patients With Non-fluent Aphasia Recruiting NCT00903266 Phase 3
47 Sodium Oxybate in Spasmodic Dysphonia and Voice Tremor Recruiting NCT03292458 Phase 2, Phase 3 Sodium Oxybate
48 Efficacy of Tympanostomy Tubes for Children With Recurrent Acute Otitis Media Recruiting NCT02567825 Phase 3
49 Clinical Trial of Efficacy and Safety of Tenoten for Children in the Treatment of Specific Developmental Disorders of Scholastic Skills in Children Recruiting NCT03159104 Phase 3 Tenoten for children;Placebo
50 Use of Local Intraoperative Steroid in MIS TLIF Active, not recruiting NCT03308084 Phase 3 Methylprednisolone;Dexamethasone

Search NIH Clinical Center for Speech and Communication Disorders

Cochrane evidence based reviews: communication disorders

Genetic Tests for Speech and Communication Disorders

Anatomical Context for Speech and Communication Disorders

MalaCards organs/tissues related to Speech and Communication Disorders:

38
Brain

Publications for Speech and Communication Disorders

Articles related to Speech and Communication Disorders:

(show all 33)
# Title Authors Year
1
A Pediatrician's Guide to Communication Disorders Secondary to Cleft Lip/Palate. ( 29173718 )
2018
2
Poststroke Communication Disorders and Dysphagia. ( 26522904 )
2015
3
Association between AVPR1A, DRD2, and ASPM and endophenotypes of communication disorders. ( 24849541 )
2014
4
Phenotype-genotype discordance in congenital malformations with communication disorders resembling trisomy 18 (Edwards syndrome). ( 24478819 )
2014
5
Observational assessment of communication disorders in vascular dementia patients with right hemisphere damage. ( 25323958 )
2014
6
Social communication disorder outside autism? A diagnostic classification approach to delineating pragmatic language impairment, high functioning autism and specific language impairment. ( 23639107 )
2013
7
Practitioner Review: Social (pragmatic) communication disorder conceptualization, evidence and clinical implications. ( 24117874 )
2013
8
Traumatic brain injury in veterans of the wars in Iraq and Afghanistan: communication disorders stratified by severity of brain injury. ( 24131337 )
2013
9
Nature and onset of communication disorder in pediatrics with HIV. ( 22542284 )
2012
10
Communication disorders related to cleft palate, craniofacial anomalies, and velopharyngeal dysfunction. ( 21948635 )
2011
11
An audiological communication disorder? ( 21586253 )
2011
12
Evaluation sensitivity as a moderator of communication disorder in schizophrenia. ( 19379529 )
2009
13
Work integration issues go beyond the nature of the communication disorder. ( 12036151 )
2002
14
A case-control study of EAS child and parental temperaments in selectively mute children with and without a co-morbid communication disorder. ( 12470308 )
2002
15
Profiles of communication disorder in children with velocardiofacial syndrome: comparison to children with Down syndrome. ( 11339384 )
2001
16
Re: Ward, S., 1999, an investigation into the effectiveness of an early intervention method for delayed language development in young children. International Journal for Language & Communication Disorder, 34, 243-246. ( 10884911 )
1999
17
"Pure word deafness": implications for assessment and management in communication disorder--a report of two cases. ( 10489017 )
1999
18
Evaluation of a child with communication disorder. ( 10744867 )
1999
19
Cognitive-communicative disorders of right cerebrovascular accident patients and reimbursement for treatment. ( 10597115 )
1999
20
Re: Ward, S., 1999 an investigation into the effectiveness of an early intervention method for delayed language development in young children. International Journal of Language & Communication Disorder, 34,243-246. ( 10884912 )
1999
21
Re: Ward, S., 1999 an investigation into the effectiveness of an early intervention method for the delayed language development in young children. International Journal of Language & Communication Disorder, 34, 243-264. ( 10884913 )
1999
22
Learning disabilities existing concomitantly with communication disorder. ( 9146094 )
1997
23
Thought disorder or communication disorder. ( 7663837 )
1995
24
Thought disorder or communication disorder. Linguistic science provides a new approach. ( 7788117 )
1995
25
Thought disorder or communication disorder. ( 7663838 )
1995
26
Formal communication disorder. Sign language in deaf people with schizophrenia. ( 7881785 )
1994
27
Autism AKA communication disorder. ( 7679094 )
1993
28
Communication disorder in renaissance Italy: an unreported case analysis by Hieronymus Mercurialis (1530-1606). ( 2184171 )
1990
29
Selective involvement of the auditory-verbal modality in an acquired communication disorder: benefit from sign language therapy. ( 7237115 )
1981
30
Prevalence, type, and correlates of psychiatric diagnoses in 200 children with communication disorder. ( 7320202 )
1981
31
The communication disorder in dialysis dementia: a case report. ( 7407554 )
1980
32
The pediatrician and the child with a communication disorder. "Semiverbality" in children. ( 4761178 )
1973
33
THE PREVENTION OF COMMUNICATION DISORDER BY THE USE OF A SIMPLIFIED ALPHABET. ( 14141732 )
1964

Variations for Speech and Communication Disorders

Expression for Speech and Communication Disorders

Search GEO for disease gene expression data for Speech and Communication Disorders.

Pathways for Speech and Communication Disorders

Pathways related to Speech and Communication Disorders according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.63 APOE CNTNAP2 MAPT MECP2 PSEN1 TARDBP
2 10.79 APOE MAPT PSEN1

GO Terms for Speech and Communication Disorders

Cellular components related to Speech and Communication Disorders according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 9.56 CNTNAP2 L1CAM MAPT PSEN1
2 growth cone GO:0030426 9.5 L1CAM MAPT PSEN1
3 neuronal cell body GO:0043025 9.43 APOE CNTNAP2 L1CAM MAPT PSEN1 TRPV1
4 dendrite GO:0030425 9.17 APOE C9orf72 CNTNAP2 L1CAM MAPT PSEN1
5 axolemma GO:0030673 9.16 CNTNAP2 MAPT

Biological processes related to Speech and Communication Disorders according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 post-embryonic development GO:0009791 9.65 FOXP2 MECP2 PSEN1
2 negative regulation of protein phosphorylation GO:0001933 9.61 C9orf72 PSEN1 TARDBP
3 cerebral cortex development GO:0021987 9.58 CNTNAP2 FOXP2 PSEN1
4 memory GO:0007613 9.54 MAPT MECP2 PSEN1
5 microglial cell activation GO:0001774 9.49 MAPT TRPV1
6 amyloid precursor protein metabolic process GO:0042982 9.46 APOE PSEN1
7 synapse organization GO:0050808 9.33 L1CAM MAPT PSEN1
8 astrocyte activation GO:0048143 9.32 MAPT PSEN1
9 vocal learning GO:0042297 9.26 CNTNAP2 FOXP2
10 positive regulation of amyloid fibril formation GO:1905908 8.96 APOE PSEN1
11 neuron projection development GO:0031175 8.92 CNTNAP2 L1CAM MAPT MECP2

Molecular functions related to Speech and Communication Disorders according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.63 APOE CBS FOXP2 MAPT TARDBP TRPV1
2 apolipoprotein binding GO:0034185 8.96 MAPT PLG
3 lipoprotein particle binding GO:0071813 8.62 APOE MAPT

Sources for Speech and Communication Disorders

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....